Investigating brain penetrance after oral administration of novel cannabinoid extracts in mice

Tidal Health是一家位于新不伦瑞克的持牌医用大麻生产商。他们目前正在开发新的大麻素提取物，但没有能力评估这些提取物在口服后进入大脑并影响大脑的程度;这需要在临床前动物模型中进行。因此，潮汐健康必须依赖于与基础研究人员的合作，该研究人员使用临床前动物模型来评估其提取物的可用性。达尔豪西大学的富兰克林实验室专注于神经系统疾病的小鼠模型，并能够测量小鼠大脑中的大麻素。Tidal Health和富兰克林实验室之间拟议的合作旨在量化年轻小鼠大脑中大麻素的含量，这些小鼠服用了三种新开发的提取物之一（高大麻二酚（CBD）：低δ 9-四氢大麻二酚（THC），高THC：低CBD或THC：CBD的平衡混合物），以建立这些大麻产品中活性成分的大脑渗透率。这项临床前研究对于Tidal Health在医用大麻领域的研发目标至关重要，最终重点是为特定的健康状况创造一致有效的产品。这项工作还将为富兰克林实验室的学员提供应用神经科学研究的重要经验，以及与一家不断发展的加拿大公司建立关系的机会。

Tidal Health is a licensed medical cannabis producer based in New Brunswick. They are currently developing new cannabinoid extracts but do not have the capability to assess the extent to which these extracts can enter into and affect the brain following oral administration; this needs to be performed in a pre-clinical animal model. Thus, Tidal Health must rely on a collaboration with a basic researcher that uses pre-clinical animal models in order to assess the usability of their extracts. The Franklin laboratory at Dalhousie University focuses on mouse models of neurological disease, and are able to measure cannabinoids in the mouse brain. The proposed collaboration between Tidal Health and the Franklin laboratory aims to quantify the amount of cannabinoids in the brain of young mice administered one of three newly developed extracts (a high cannabidiol (CBD):low delta9-tetrahydrocannbinol (THC), high THC:low CBD, or a balanced mixture of THC:CBD) in order to establish the brain penetrance of active ingredients in these cannabis products. This pre-clinical research is critical for Tidal Health's research and development goals in the field of medical cannabis, which are ultimately focused on creating consistent and effective products for specified health conditions. This work will also provide trainees in the Franklin laboratory important experience in applied neuroscience research, as well as the opportunity to establish relationships with a growing Canadian company.